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A TUMOUR MODEL iS presented in which
uiniform reoxygenation ofhypoxic tumour
cells occurs initially during a course of
radiotherapy, followed by failure of the
remaining hypoxic cells to undergo reoxy-
genation during the latter part oftherapy.
This model may reflect the behaviour of
certain types ofhuman cancer (see below).
It is suggested that misonidazole (MISO)
could be effectively used in this tumour
model when given towards the end of a
course of radiation and in high doses. An
example ofa therapeutic protocol based on
these premises is presented.
MISO and reoxygenation. The tumour
control probabilities for a rapidly reoxy-
genating mouse tumour treated with
various fractionation schedules have been
studied by Fowler et al. (1976). No
improvement in tumour control prob-
ability was obtained by adding MISO to
the optimum radiation fractionation
schedule, although the drug was of benefit
for poor fractionation schedules. Con-
versely, when a poorly reoxygenating
tumour was studied, the tumour control
probability was increased for all fractiona-
tion schedules by the addition of MISO
(Sheldon & Fowler, 1978).
A possible explanation for this is that
the proportion of hypoxic cells may
remain constant (and not decrease) in a
tumour undergoing reoxygenation, as the
total number of tumour cells decreases
during radiation therapy. This has been
documented during fractionated radiation
in an experimental mouse by van Putten &
Kallman (1968). This may be a conse-
quence of the cell kinetics of reoxygena-
tion. Tumour cells within a tumour cord
surrounding a capillary migrate with
proliferation from the well oxygenated
zone adjacent to the capillary to the
hypoxic region and then to the anoxic
region where they undergo cell death
(Tannock, 1970). After a single dose of
radiation, changes in tumour oxygenation
with time are dependent on the changes in
the tumour micro-architecture, an initial
thinning of the cord width being followed
by a widening ofthe cord width (Tannock
& Howes, 1973). The former change may
result in hypoxic tumour cells, which
would otherwise have undergone cell death
through passage to the anoxic zone in an
untreated tumour, remaining viable after
radiation. As a result of the latter process
additional hypoxic cells may be produced.
Thus even though MISO as an adjunct to
radiation might result in a decrease in the
proportion of hypoxic cells, this will only
be transient. MISO administration is
consequently of little value in the tumour
model when reoxygenation is taking place,
provided the optimal radiation fractiona-
tion schedule is being used.
It is hypothesized for the tumour model
that reoxygenation fails to take place
during the latter part of therapy. A
possible cause of this in patients is the
effect of radiation on the fine vasculature
of the tumour. Swelling, degeneration and
hyperplasia of endothelial cells may ensue
after radiation, together with the forma-
tion ofmicrothrombi, and these may cause
capillary obstruction (Rubin & Cassarett,,MISONII)AZOLE AND HYPOXIC TUAIOUR CELLS
1968). These authors have, however, noted
that the vascular effects are decreased by
the use of small and multiple radiation
doses in experimental tumours, but these
received incomplete tumoricidal doses.
The inflammatory reaction associated with
radiation damage results in the leakage of
colloids and the deposition of fibrin (Law
& Thomlinson, 1978), which may impair
oxygen diffusion. Increased proliferation
of endothelial cells in tumours has been
documented (Denekamp, 1982) and as
these cells are well oxygenated they may
be relatively radiosensitive. The effects of
radiation on the fine vasculature have
been observed soon after radiation (e.g.
Faiardo & Stewart, 1971; Law & Thomlin-
son, 1978; Kawamura & Fujiwara, 1973)
in experimental systems and are fre-
quently observed by pathologists in
patients treated with planned preopera-
tive radiation and surgery using conven-
tional fractionation. These effects of
radiation on tumour fine vasculature may
impair reoxygenation towards the end of a
course of fractionated therapy which is
spread over 6 weeks.
The mechanism of reoxygenation can-
not be fully explained by cell death and
other factors, such as impaired metabolism
of oxygen by radiation-sterilized, but still
viable cells may play a role (Kallman,
1972). In the absence of this information
the possibility that reoxygenation is a
limited process in certain types oftumours
must be considered. In the tumour model,
reoxygenation is assumed to fail during
therapy and a high proportion of hypoxic
cells will subsequently rapidly develop
with continued radiation.
MISO will be of great value in sensi-
tizing these remaining hypoxic cells, as
their sterilization will be critical to the
achievement oftumour cure.
MX[ISO and radiation dosages. The sen-
sitizer enhancement ratio of MISO is
related to the concentration of the agent
(Asquith et al., 1974). The total dose of
MISO which can be administered during a
course ofradiotherapy is, however, limited
by the drug's neurotoxicity (Dische et al.,
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1979). The major advantage of fractiona-
tion in terms of the reduction in the
number ofhypoxic cells, namely reoxygen-
ation, is no longer applicable towards the
end of therapy in the tumour model. The
largest cell kill for hypoxic cells will thus
be obtained by using MISO in high doses
and with a few relatively large radiation
fractions. In order to maintain a constant
relative biological effectiveness (RBE) for
the radiation fractionation schedule,
which includes doses of radiation as
compared to the fractionation schedule
which it is replacing, the size and the
number of large radiation fractions will
require adjustment.
Large fractions of radiation will, how-
ever, adversely affect radiobiological
repair of normal tissue cells and measures
to prevent normal tissue damage will be
indicated (see below).
The survival curves for the hypoxic cells
in the tumour model are illustrated in Fig.
1. The Do for the hypoxic cells undergoing
reoxygenation mirrors the Do of the
oxygenated tumour cells, assuming that
the optimal radiation fractionation
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schedule is being used? It will be negligibly
affected by MISO administration. The Do
for the remaining hypoxic cells which do
not undergo reoxygenation will be approx-
imately 3 x greater. An arbitrary (sensi-
tization enhancement ratio) (SER) of2 has
been used to determine the survival curve
of the hypoxic cells irradiation in the
presence of MISO. The large fractions of
radiation used with MISO have been
normalized to the fractionation schedule
initially used for comparative purposes.
Clinical applications.-This tumour
model may reflect the behaviour ofcertain
tumours in patients, although it is obvi-
ously simplified and any transition from
active reoxygenation to its termination
will be more gradual.
A radiation fractionation schedule for
use clinically together with MISO has been
devised on the premises outlined above. It
consists ofan initial course of2 Gy in daily
fractions to a dose of 40 Gy over 4 weeks,
which probably is an efficient fractionation
schedule in the presence of reoxygenation
in view ofits widespread empirical adapta-
tion. This is followed by 6 Gy given twice,
one week apart together with high doses
ofMISO to a dose of 12 Gy. The interval of
one week between the 2 large fractions is
used in order to prevent increased normal
tissue damage which may result from the 2
large fractions and is based on the
reasonable expectation that the slowly
dividing hypoxic tumour cells will repop-
ulate to a lesser extent than the normal
tissue cells. In addition coned down
volumes can be used for the large
fractions. This approach has been clinic-
ally since 1979 in pilot studies in the
treatment of bladder carcinoma. In an
initial pilot study MISO was used orally
only, after which it was used in a second
pilot study both orally and intravesically
in order to boost further the tumour
concentration ofMISO. The dose ofMISO
used in the second pilot study was 3e0 g/m2
orally 4 h before radiation.
Improvement in the complete response
rate at cystoscopy in the treatment of T2
Grade III and T3 bladder carcinoma has
been obtained in 22 patients treated with
radiation plus oral and intravesical MISO
compared with 63 patients treated by
radical irradiation between 1972 and 1977
who served as historical controls (73% V8
43%-significant at 5% level of confi-
dence-x2 test). Improvement has also
been maintained at a mean follow up of
13-3 months and there has been no MISO
neurotoxicity in this pilot study. There
have been no late radiation complications
in either of the 2 pilot studies, 14 patients
having been followed up for between 12
and 24 months (Abratt et al., submitted for
publication).
Alternative and rational approaches
based on different premises to the clinical
use ofMISO have been suggested byothers
(Denekamp et al., 1978, 1980). Therapeutic
protocols which effectively use MISO are
likely to be dependent on the tumour's
pattern of reoxygenation. This has been
found to vary in different tumour systems
in experimental animals (Kallman, 1972).
In the absence of this information in
patients, clinical work is proceeding
empirically to a large extent. Information
on reoxygenation in human tumours will
be ofgreat value not only in the design of
efficient radiation fractionation schedules
but also the planning of therapeutic
protocols which include radiosensitizers,
high linear energy transfer radiation and
hyperthermia.
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